Everest Medicines

News

19 2022/09

Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
26 2022/08

Everest Medicines Announces the Departure of CEO, Kerry Blanchard
24 2022/08

Everest Medicines Announces Interim Results for First Half of 2022
16 2022/08

Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy^® in Asia Territories
11 2022/08

Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
18 2022/07

Everest Medicines Announces European Commission Grants Approval of Kinpeygo^® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
10 2022/06

Everest Medicines Announces Approval of Trodelvy^® in China for Second-Line Metastatic Triple-Negative Breast Cancer
04 2022/06

Everest Medicines’ Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy^® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
24 2022/05

Everest Medicines’ Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
07 2022/04

Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
06 2022/04

Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
31 2022/03

Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号